Candel therapeutics reports second quarter 2023 financial results and recent corporate highlights

Needham, mass., aug. 10, 2023 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the second quarter ended june 30, 2023, and provided a corporate update.
CADL Ratings Summary
CADL Quant Ranking